Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

November 30, 2025

Conditions
HRD 100 Gene Expression HighTriple Negative Breast Cancer
Interventions
DRUG

Talazoparib

"The recommended dose is 1 mg talazoparib once daily. Patients should be treated until disease progression or unacceptable toxicity occurs. Daily dosing of talazoparib can be interrupted for recovery from toxicity for up to 28 days. For interruptions longer than 28 days, treatment at the same or a reduced dose can be considered based on the if evidence of response or clinical benefit to talazoparib is noted.~Missing dose If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~Dose adjustments:~To manage adverse drug reactions, interruption of treatment or dose reduction based on severity and clinical presentation should be considered."

Trial Locations (1)

59100

RECRUITING

University Malaya Medical Centre, Kuala Lumpur

Sponsors
All Listed Sponsors
collaborator

Cancer Research Malaysia

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

Pantai Hospital Kuala Lumpur

UNKNOWN

collaborator

Hospital Sultan Ismail

UNKNOWN

lead

University of Malaya

OTHER